Jasper Therapeutics (JSPR)
(Delayed Data from NSDQ)
$20.04 USD
+0.21 (1.06%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $20.14 +0.10 (0.50%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth B Momentum D VGM
Cash flow Statements
Fiscal Year End for Jasper Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -64.47 | -37.69 | -30.64 | -0.59 | 0.00 |
Depreciation/Amortization & Depletion | 1.11 | 0.98 | 0.38 | 0.00 | 0.00 |
Net Change from Assets/Liabilities | 5.10 | -0.65 | 1.62 | 0.33 | -0.22 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 6.19 | -8.50 | -5.04 | -0.38 | -0.15 |
Net Cash From Operating Activities | -52.07 | -45.86 | -33.68 | -0.64 | -0.37 |
Property & Equipment | -0.27 | -0.58 | -2.43 | 0.00 | 0.00 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.20 | 0.00 |
Net Cash from Investing Activities | -0.27 | -0.58 | -2.43 | 0.20 | -100.00 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 101.93 | 0.06 | 10.99 | 0.00 | 0.00 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 95.27 | 0.00 | -0.18 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -0.96 | 0.00 | -5.29 | 0.00 | 101.76 |
Net Cash from Financing Activities | 100.97 | 0.06 | 100.97 | 0.00 | 101.58 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 48.64 | -46.38 | 64.86 | -0.44 | 1.21 |
Cash at Beginning of Period | 38.67 | 85.05 | 20.18 | 1.21 | 0.00 |
Cash at End of Period | 87.30 | 38.67 | 85.05 | 0.77 | 1.21 |
Diluted Net EPS | -6.18 | -10.30 | -26.90 | -2.40 | NA |
Fiscal Year End for Jasper Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | NA | -28.31 | -13.73 | -64.47 | -47.88 |
Depreciation/Amortization & Depletion | NA | 0.59 | 0.29 | 1.11 | 0.83 |
Net Change from Assets/Liabilities | NA | -2.60 | -3.60 | 5.10 | 6.53 |
Net Cash from Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | NA | 2.91 | 1.31 | 6.19 | 4.95 |
Net Cash From Operating Activities | NA | -27.42 | -15.74 | -52.07 | -35.59 |
Property & Equipment | NA | -0.18 | -0.03 | -0.27 | -0.04 |
Acquisition/ Disposition of Subsidiaries | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Investing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | NA | -0.18 | -0.03 | -0.27 | -0.04 |
Uses of Funds
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | NA | 47.53 | 47.35 | 101.93 | 101.90 |
Issuance (Repayment) of Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | NA | 0.00 | 0.00 | -0.96 | -0.66 |
Net Cash from Financing Activities | NA | 47.53 | 47.35 | 100.97 | 101.24 |
Effect of Exchange Rate Changes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | NA | 19.93 | 31.59 | 48.64 | 65.62 |
Cash at Beginning of Period | NA | 87.30 | 87.30 | 38.67 | 38.67 |
Cash at End of Period | NA | 107.24 | 118.89 | 87.30 | 104.28 |
Diluted Net EPS | NA | -0.97 | -1.03 | -1.48 | -1.60 |